Progenika Biopharma SA creates a subsidiary in the UK
Progenika Biopharma SA, an innovative Spanish company developing microarrays for genetic diagnosis, today announced the creation of a new subsidiary, Progenika Biopharma Ltd, to be based in the UK. The UK facility, which it is expected to come on line in Q1 2006, will initially process genetic diagnostic tests developed by the parent company in their headquarters and research facility on the outskirts of Bilbao, Spain.
Progenika Ltd will provide a diagnostic service based on the unique Sendagene(TM) platform for the diagnosis of genetically complex diseases. Dr Laureano Simon, company founder and CEO, underlined the enormous potential of the Sendagene(TM) technology for the early diagnosis of potentially debilitating conditions allowing doctors to treat and control important diseases suffered by their patients such as Familial Hypercholesterolaemia and Inflammatory Bowel Disease. The creation of Progenika Biopharma Ltd brings the possibility of individualized medicine one step closer to reality he said in a statement today.
Topics
Organizations
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.